3 transcripts
ADAP
Earnings call transcript
NASDAQ
2024 Q1
15 May 24
for at least 6 months. It's evenly comprised of patients with synovial sarcoma and myxoid/round cell liposarcoma. So will present the efficacy data and safety
ADAP
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
analysis, where we've looked at other competitor products, we think our TCR does have a different safety efficacy profile, which we are very happy
ADAP
Earnings call transcript
NASDAQ
2023 Q2
9 Aug 23
?
Yes. Thanks, Ad. Cohort 2 data is going to be in the BLA from a safety perspective. We have not discussed with the FDA to provide updated efficacy data
- Prev
- 1
- Next